The Memo: Calla Lily Clinical Care Developing Callavid as the Essential Drug Delivery Platform for Women

Under the direction of co-founders Dr. Lara Zibners and Thang Vo-Ta, Calla Lily Clinical Care is reimagining vaginal drug delivery with its CallavidⓇ device — engineering a next-generation platform that improves both clinical outcomes and patient experience in women’s health.

“Our revolutionary Callavid platform hugely increases the possibilities for intravaginal drug delivery by enabling treatments with enhanced efficacy, lower drug doses, and minimized side effects,” said Vo-Ta.

With its pioneering drug-device combination product, NIHR-funded clinical trial shortly underway, and a platform approach initially addressing miscarriage, IVF, and vaginal microbiome disorders, Calla Lily is redefining what it means to put women’s needs first in medical innovation.

Origin Story

The idea for Calla Lily Clinical Care was born from personal experience. Dr. Lara Zibners, a board-certified pediatrician and emergency medicine specialist, had gone through seven rounds of IVF — all of which had failed. Each cycle involved either painful intramuscular injections or leaky vaginal pessaries that caused anxiety, inconvenience, and uncertainty.

“Every single woman who goes through this process, when opening the progesterone needle or pessary, thinks ‘there HAS to be a better way,’” Zibners said. “Well, we have that better way.”

Zibners partnered with Thang Vo-Ta, a former Goldman Sachs private equity investor and serial entrepreneur, who first developed an earlier version of Callavid as an FDA-cleared leak-free period care tampon-pantyliner combination.

The realization that their technology could transform drug delivery for critical women’s health conditions led them to establish Calla Lily Clinical Care, combining Zibners’ medical expertise with Vo-Ta’s business acumen to create a company dedicated to revolutionizing women’s health.

The company is a Certified B Corp and is based in London, UK.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-calla-lily-clinical-care-developing-callavid-as-the-essential-drug-delivery-platform-for-women 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more